Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410954 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02410954 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 14 participants.
The verdict
NCT02410954, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Locus coeruleus (LC) norepinephrine (NE) neuron activity has been convincingly linked to regulation of acute fear. This study will address whether LC NE activity examined through pupil measures will reflect carbon dioxide (CO2) induced fear-responses in humans and if transcranial direct current stimulation (tDCS) can mitigate these effects. A 2 year R21 phase establishing feasibility, tolerability, safety, and proof-of-concept (POC) in terms of capacity to engage LC NE neurons with tDCS, followed by a 3 year R33 parallel-group, double-blind, randomized, controlled trial will determine the degree to which engaging LC NE neurons with tDCS improves clinical symptoms.
Interventions
- DEVICE NeuroConn Direct Current stimulator Multiple Channel -4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12 |
| Est. Completion | 2019-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02410954
The ClinicalTrials.gov registry entry for NCT02410954 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NeuroConn Direct Current stimulator Multiple Channel -4 is the first listed.
NCT02410954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02410954 about?
NCT02410954 is a clinical study titled "Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear". Locus coeruleus (LC) norepinephrine (NE) neuron activity has been convincingly linked to regulation of acute fear. This study will address whether LC NE activity examined through pupil measures will reflect carbon dioxide (CO2) induced fear-responses in humans and if transcranial direct current stim...
What is the current status of trial NCT02410954?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT02410954?
The interventions under investigation include: NeuroConn Direct Current stimulator Multiple Channel -4 (DEVICE).
Who is sponsoring clinical trial NCT02410954?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.